Clinical Trials Logo

Heart Diseases clinical trials

View clinical trials related to Heart Diseases.

Filter by:

NCT ID: NCT05618223 Not yet recruiting - Heart Failure Clinical Trials

Dapagliflozin Effect on Rheumatic Mitral Stenosis

Dapa-Rhemis
Start date: December 1, 2022
Phase: Phase 3
Study type: Interventional

Rheumatic mitral stenosis remains a health problem in developing countries. Progressive fibrosis of the valves and myocardium is the main pathophysiology that plays an important role. Dapagliflozin has various beneficial effects on the heart by reducing fibrosis, reducing inflammation, and improving patient quality of life. However, the role of this therapy is unknown in patients with rheumatic mitral stenosis.

NCT ID: NCT05580510 Not yet recruiting - Heart Failure Clinical Trials

" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "

Start date: February 6, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The treatment of adult patients with congenital heart disease (ACHD) and heart failure (HF) represents a great challenge since, to date, there is no standardized guideline for this specific population. Although new treatments for HF have been proposed, such as Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors and neprilisin and angiotensin receptor inhibitors, the benefit of these drugs in patients with HF associated with congenital heart disease in adults has not yet been demonstrated. For this reason, this study pretends to evaluate the efficacy of empagliflozin and sacubitril/valsartan in this population.

NCT ID: NCT05568849 Not yet recruiting - Clinical trials for Congenital Heart Disease

Optical Coherence Tomography Angiography (OCTA) in Children's Cardiac Surgery

OCTA
Start date: October 2022
Phase: N/A
Study type: Interventional

Around 3500 children including 1,000 babies a year in the UK require heart surgery. Open-heart repairs involve the heart being stopped, while blood is pumped around the body using a cardiopulmonary bypass machine. Following complex operations, the patient may temporarily develop poor heart function, leading to reduced organ blood supply. Low heart output leads to post-operative complications or even death. The current methods to assess cardiac output and to see if vital organs, especially the brain, are receiving enough blood flow, are indirect and can be inaccurate. If we find a better way to detect and then avert or ameliorate periods of poor cardiac output and / or reduced brain perfusion, then this would be helpful for clinicians and could lead to better outcomes for children. We believe that optical coherence tomography angiography (OCTA), a non-invasive way to image the blood vessels in the retina at the back of the eye, could help us to assess cardiac output and brain perfusion. The OCTA machine was approved for use in humans in 2019 and given a CE Marking, but it has previously been used mainly in the management of eye diseases. There is a small amount of experience with its use in critically ill adults. We plan a pilot study to see if it is possible to use the OCTA machine at key time points, before, during and after children's heart operations, in 30 patients. We will study the images taken with OCTA machine to see if they are of good quality and we will analyze the images to see whether or not the expected changes in cardiac output and brain perfusion that occur with heart surgery can be detected as changes in blood flow in the back of the eye. Depending on the success of this pilot, we will plan further studies.

NCT ID: NCT05559424 Not yet recruiting - Clinical trials for Ischemic Heart Disease

Comparison of Results Achieved by Different Ballooning Techniques in Bifurcation Stenting

CRABBIS
Start date: October 2022
Phase: N/A
Study type: Interventional

Single-stent strategy with provisional approach represents the gold standard for percutaneous coronary intervention of bifurcation lesions, and, according to European Bifurcation Club, performing provisional approach presents two steps considered as mandatory: "crossover stenting" in main vessel (MV) and subsequent post-dilation or "POT" (proximal optimization technique). While consensus exists regarding these first two steps, the exact optimal following sequence in case of side branch (SB) jeopardize after main vessel stenting is still a matter of debate. Actually, the two most used techniques in this setting are represented by the simultaneous inflation of two balloons located respectively in the MV and SB followed by a second POT (POT/kissing balloon/POT technique) and the isolated inflation of a balloon placed in the SB followed by a second POT (POT/SIDE/POT technique). The objective of this study is to compare the configuration achieved with POT/KISS/POT (PKP) and POT/SIDE/POT (PSP), using the "cutting edge" high-resolution intracoronary imaging modality (Optical Coherence Tomography, OCT).

NCT ID: NCT05553717 Not yet recruiting - Clinical trials for Gastro-Intestinal Disorder

Clinical Study Evaluating the Gastroprotective Effect of Carvedilol in Patients With Ischemic Heart Disease on Aspirin Therapy

Start date: October 2022
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the possible efficacy of Carvedilol as gastroprotective agent against aspirin-induced upper gastro-intestinal complications in patients with ischemic heart disease (IHD).

NCT ID: NCT05546008 Not yet recruiting - Clinical trials for Congenital Heart Disease

Comparison Between Multislice CT and Echocardiography in Diagnosis of Pediatric Congenital Heart Disease

CHD
Start date: September 10, 2022
Phase:
Study type: Observational

1. Assesment of pediatric CHD by Echocardiography and Multislice CT before operation and compare with surgical results. 2. Compare echocardiogram and 128-Multislice spiral computed tomography(MSCT) in the diagnosis of pediatric CHD. 3. Confirm echocardiographic finding in pediatric CHD by(MSCT) and to show the role of MSCT in diagnosing of extra-cardia anomalies. 4. to show the role of MSCT as a useful tool in defintive diagnosis of congenital heart disease before operations which assist surgeons

NCT ID: NCT05540223 Not yet recruiting - Clinical trials for Coronary Artery Disease

Safety and Clinical Performance of the DREAMS 3G Resorbable Magnesium Scaffold System

BIOMAG-II
Start date: May 2024
Phase: N/A
Study type: Interventional

The objective of this study is to assess the safety and efficacy of the DREAMS 3G in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to a contemporary drug eluting stent (DES).

NCT ID: NCT05524324 Not yet recruiting - Clinical trials for Congenital Heart Disease

Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT

RIGHT-CRT
Start date: September 2022
Phase: N/A
Study type: Interventional

The main objective of RIGHT-CRT is to assess the impact/efficacy of CRT on functional capacity in ACHD patients with SRV.

NCT ID: NCT05477940 Not yet recruiting - Clinical trials for Coronary Heart Disease

Study on Absorbable Zinc Alloy Drug Eluting Coronary Stent System

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This trial is a prospective, two center single group registration pilot trial aiming to evaluate the product safety, and provide information for the later confirmatory test design according to the results.

NCT ID: NCT05473325 Not yet recruiting - Obesity Clinical Trials

Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)

BRANCH-P
Start date: January 1, 2023
Phase:
Study type: Observational

This research programme seeks to combine the resources of NHS primary care, with the leading spectroscopic work in low-magnetic fields of the Wilson Group (Nottingham Trent University) to demonstrate the potential for benchtop Nuclear Magnetic Resonance (NMR) spectroscopy in human clinical pathology. This is an instrument assessment study for point of care viability which will also result in enhanced patient care (pending their consent) in blood screenings and metabolic health data.